How Wegovy vs Mounjaro Doses Compare in UK Clinical Practice
Wegovy vs Mounjaro Doses: Understanding the Clinical Evidence
When comparing Wegovy vs Mounjaro doses, UK patients need evidence-based information about how these prescription-only medicines perform in clinical trials. Wegovy (semaglutide) demonstrated significant results in the landmark STEP trials, with patients achieving approximately 15% average weight loss at 68 weeks when combined with reduced-calorie diet and increased physical activity. The medication works as a GLP-1 receptor agonist, mimicking natural fullness hormones to reduce appetite and promote satiety after smaller meals.
Mounjaro (tirzepatide) operates through a different mechanism as a dual GIP and GLP-1 receptor agonist, offering an alternative approach to weight management. However, these medications cannot be directly compared through trial percentages due to different study designs, patient populations, and endpoints. Both Wegovy and Mounjaro are available from EverydayMeds through our GPhC-registered pharmacy (#9012878), with your prescriber helping determine which treatment may be most appropriate for your individual circumstances.
Wegovy vs Mounjaro Doses: UK Pricing and Value Comparison
Understanding the cost implications when comparing Wegovy vs Mounjaro doses helps UK patients make informed decisions about their weight management investment. Wegovy follows a structured 20-week escalation schedule starting at £79.99 for the 0.25mg dose (weeks 1-4), progressing to £94.99 for 0.5mg (weeks 5-8), £99.99 for 1mg (weeks 9-12), £139.99 for 1.7mg (weeks 13-16), and reaching £209.99 for the 2.4mg maintenance dose. New customers apply discount code FIRST40 at checkout, whilst returning customers use code DOSE25.
EverydayMeds offers convenient bundle options for the Wegovy dosing journey, including our Intro Trio (0.25mg, 0.5mg, and 1mg pens) for £299.99, providing the first 12 weeks of treatment in one order. Our Ultimate Stability Trio supplies three months of 2.4mg maintenance doses for £649.99, ensuring consistent supply without repeated ordering. These bundles provide convenience and Confirmed Availability rather than cost savings, with fewer orders and single deliveries simplifying the treatment process.
STEP Trial Evidence for Wegovy vs Mounjaro Doses
The STEP clinical trial programme provides robust evidence for Wegovy's effectiveness when comparing Wegovy vs Mounjaro doses and outcomes. In STEP 1, patients taking Wegovy alongside lifestyle interventions achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, as published by Wilding et al. in the New England Journal of Medicine, 2021. STEP 3 demonstrated even greater results with intensive behavioural therapy, showing approximately 16% average weight loss.
Long-term sustainability data from STEP 5 revealed approximately clinically studied weight loss maintained at two years, whilst the SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events. These results demonstrate that Wegovy, when used alongside reduced-calorie diet and increased physical activity, may support significant and sustained weight management in clinical trial settings.
How Wegovy Works: Mechanism Behind the Doses
Understanding how Wegovy works helps explain why the dosing schedule matters when comparing Wegovy vs Mounjaro doses and mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of glucagon-like peptide-1, a natural hormone released in response to food intake. This medication works on appetite centres in the brain, reducing hunger signals and promoting feelings of fullness after consuming smaller portions. The gradual dose escalation from 0.25mg to 2.4mg allows the body to adapt to the medication's effects whilst minimising potential gastrointestinal side effects. Wegovy may also reduce food cravings and the preoccupation with food that many patients experience, supporting long-term adherence to reduced-calorie eating patterns alongside increased physical activity.
EverydayMeds Ordering Process for Wegovy vs Mounjaro Doses
Accessing either medication when comparing Wegovy vs Mounjaro doses requires a streamlined but thorough clinical assessment process through our GPhC-registered pharmacy. Patients complete a comprehensive 3-minute online clinical questionnaire covering medical history, current medications, previous weight loss attempts, and specific health conditions that may affect treatment suitability. Our qualified prescribers review each application within 3 working days (express 24-hour service available), ensuring appropriate prescribing and patient safety before dispensing either prescription-only medicine. Once approved, medications are dispatched via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. The entire process from assessment to delivery typically takes 4-5 working days, with express options available for established patients requiring urgent refills.
Storage and Practical Considerations: Wegovy vs Mounjaro Doses
Practical storage requirements differ significantly when comparing Wegovy vs Mounjaro doses, offering important advantages for UK patients with varied lifestyles. Wegovy pens must be stored in the refrigerator at 2-8°C before first use but can remain stable at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration. This provides considerable flexibility compared to Mounjaro's 21-day room temperature stability, making Wegovy more suitable for frequent travellers, business professionals, or patients without consistent refrigerator access. The FlexTouch pen delivery system offers precise dosing with clear dose selection windows and audible click confirmation. Each pen contains four weekly doses, with the dose escalation schedule requiring different pen strengths every 4 weeks during the initial 16-week titration period before reaching the 2.4mg maintenance dose.
UK Clinical Outcomes: Wegovy vs Mounjaro Doses in Real-World Practice
Real-world UK clinical experience provides additional context when evaluating Wegovy vs Mounjaro doses beyond controlled trial environments. NHS specialist weight management services report that patients often respond differently to GLP-1 receptor agonists versus dual GIP/GLP-1 receptor agonists, with individual variation in appetite suppression, gastrointestinal tolerance, and weight loss patterns. Some patients find the Wegovy dose escalation schedule more gradual and tolerable, whilst others may prefer Mounjaro's different titration approach. NICE guidance TA875 recommends Wegovy with specialist weight management support, emphasising the importance of comprehensive lifestyle intervention alongside medication.
Patient adherence rates in UK clinical practice suggest that storage convenience, injection frequency, and dose escalation tolerability significantly impact long-term treatment success. The 6-week room temperature stability of Wegovy vs Mounjaro doses provides practical advantages for maintaining consistent weekly dosing schedules, particularly during travel, work commitments, or family holidays when refrigerator access may be limited.
Making Your Decision: Wegovy vs Mounjaro Doses Through EverydayMeds
Both Wegovy and Mounjaro represent evidence-based approaches to prescription weight management, each with distinct dosing schedules and mechanisms of action that may suit different patient needs. Our clinical team at EverydayMeds provides personalised guidance during the assessment process, considering your medical history, lifestyle factors, previous treatment responses, and individual preferences when discussing Wegovy vs Mounjaro doses. The decision ultimately rests with you and your prescriber, based on clinical suitability rather than one medication being universally "better" than another. Starting your assessment today with discount code FIRST40 for new customers or DOSE25 for returning patients ensures access to both treatment options through our secure, regulated pathway. Visit https://everydaymeds.co.uk/collections/wegovy to begin your clinical assessment and take the first step towards evidence-based weight management support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
